Strong Patent Portfolio CureVac holds over 25 years of research with nearly 1,000 mRNA patents, highlighting its robust intellectual property which can be leveraged for collaborative development or licensing opportunities in advanced mRNA therapeutics and vaccines.

Strategic Acquisition Potential The ongoing acquisition by BioNTech and recent high-profile buyout interest signal increased market validation and growth potential, presenting sales opportunities in partnership services, licensing, and private label collaborations for companies seeking to expand their mRNA capabilities.

Financial Strength With a cash position expected to sustain operations into 2028 and revenue in the $50M to $100M range, CureVac is well-positioned for long-term partnership opportunities, especially in the development and commercialization of oncology and prophylactic mRNA products.

Market Leadership in mRNA As a pioneer in mRNA technology with a proven track record in COVID-19 vaccine development, CureVac offers opportunities for technology licensing, joint ventures, and product co-development with healthcare companies aiming to enhance their mRNA portfolio expertise.